- AdventHealth
During his 30-year tenure at AdventHealth in Central Florida, Neil Finkler, M.D., has left an immeasurable imprint on the organization, starting his career founding AdventHealth Orlando’s gynecologic oncology program and fellowship program and ending it as the hospital system’s chief clinical officer. As he prepares to retire, he reflects on his three decades with AdventHealth during this Becker’s Healthcare Podcast.
“I’m really proud of my dedication to involving research into clinical care,” said Finkler. “How we move the needle forward, especially in oncology, is to do studies, make discoveries and publish the research to improve the medical community. I also believe it’s our responsibility to train the clinicians who will take care of the next generation, so adding the gynecologic oncology fellowship program was a step forward for the hospital system.”
Coming from major academic medical centers such as Boston University School of Medicine, Harvard Medical School, and Mount Sinai School of Medicine in New York where the vast majority of the practicing physicians were academically based, transitioning to Central Florida in the mid-1990s was a transition for Finkler.
During his tenure at AdventHealth, Finkler has watched a dramatic morph from a private practice model to what Finkler refers to as a “priva-demic” model, where there is now a combination of employed practitioners and private practice physicians, in addition to a robust graduate medical education (GME) department including an array of residency and fellowship programs.
“It’s the best of both worlds because you have high functioning, high producing clinicians alongside those pursuing academics, whether it be teaching medicine to the next generation or advancing the field through research, innovation and creative ideas,” he said.
He also credits the pandemic for accelerating advancements in the healthcare industry.
“Pre-COVID, medicine evolved very slowly, and it would take us years to change what we did and what was considered the best practice,” said Finkler. “The pandemic forced all of us in medicine to take chances because we couldn’t wait – we had to innovate because the information evolved at a rate I’ve never seen before, and it required us to act just as quickly.”
Finkler thinks the silver lining to COVID is the ability to be nimble and adjust when necessary. In fact, he and his colleague published an article in the New England Journal of Medicine outlining five lessons learned during the Delta surge.
Finkler also takes a moment to reflect on the future of medicine and clinical care in the podcast.
“I think there's lots of challenges ahead, but I think the beautiful thing is that that we've got a group of young, talented people in health care today and they will figure out how we move forward in medicine,” he said. “I'm really quite hopeful for the future and confident that they will be able to do this and bring health care to where we need it to be.”
To listen to the full Becker’s Healthcare podcast and learn more about Finkler’s hopes for clinicians in the future, click here.
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...